Quantcast
Last updated on April 21, 2014 at 12:39 EDT

Latest Keyhole limpet hemocyanin Stories

2008-07-18 09:01:12

Biovest, a subsidiary of Accentia, has announced positive data from a pivotal trial of BiovaxID in lymphoma, and the vaccine now stands a good chance of becoming the first therapeutic cancer vaccine to gain approval in the seven major markets. However, despite this breakthrough, a number of economical and logistical issues could prevent the vaccine from achieving significant market penetration. Biovest's BiovaxID prolonged disease-free survival in patients with follicular lymphoma, meeting...